24 completed, 16 recruiting, 8 unknown, 7 terminated. 20 Phase 3, 10 Phase 2, 4 Not applicable, 4 Phase 4, 3 Phase 1.
Follow Polymyalgia Rheumatica: new trials by email Literature Review of Polymyalgia Rheumatica trials Research Report on Polymyalgia Rheumatica
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DNA Methylation in PMR Polymyalgia Rheumatica (PMR) | Not yet recruiting | Dartmouth-Hitchcock Medical Center | 50 | 2026-08-31 | 2026-08-26 | |
| Using Personalized Rehabilitation to Reduce Disease and Increase Activity of Patients With Polymyalgia Rheumatica Movement Pattern Training (MoveTrain), Usual Care - Polymyalgia Rheumatica (PMR) | Not applicable | Recruiting | Washington University School of Medicine | 20 | 2026-08-15 | 2026-11-05 |
| Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE) biobank sample collection - Polymyalgia Rheumatica, Inflammatory Rheumatism | Not yet recruiting | University Hospital, Brest | 400 | 2026-07-01 | 2026-06-08 | |
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica Sarilumab, Placebo - Polymyalgia Rheumatica | Phase 3 | Recruiting | Sanofi | 300 | 2026-05-12 | 2026-10-21 |
| Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica Description of population - Giant Cell Arteritis (GCA), Spondylarthritis | Not yet recruiting | Hôpital NOVO | 10 | 2026-02-01 | 2026-02-06 | |
| Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet, Placebo 4 mg - Polymyalgia Rheumatica (PMR) | Phase 3 | Recruiting | University Hospital, Brest | 140 | 2025-12-18 | 2026-08-26 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica PET/MRI, PET/CT with 18-FDG - Polymyalgia Rheumatica (PMR) | Recruiting | Kresten Krarup Keller | 149 | 2025-08-21 | 2025-10-01 | |
| Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) Olokizumab, Placebo - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | R-Pharm International, LLC | 125 | 2025-06-11 | 2026-06-30 |
| Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy Ex Vivo Assay - Rheumatic Diseases, Rheumatoid Arthritis (RA) | Recruiting | University of Bonn | 120 | 2025-04-01 | 2025-09-02 | |
| A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases. Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 10000 | 2025-01-30 | 2025-01-09 | |
| Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases Shingrix, vaccination with 2 doses of Shingrix vaccine - Systemic Vasculitis, Spondylarthropathies | Phase 4 | Enrolling by invitation | Region Skane | 240 | 2024-12-17 | 2025-01-10 |
| AYLo - AutoimmunitY and Loss of y Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex Array - Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR) | Recruiting | University of Bonn | 500 | 2024-11-15 | 2025-04-10 | |
| Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ) Additional blood samples - Giant Cell Arteritis (GCA), Polymyalgia Rheumatica (PMR) | Recruiting | Centre Hospitalier Universitaire Dijon | 78 | 2024-10-10 | 2025-09-09 | |
| A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy Arthritis, Polymyalgia Rheumatica | Recruiting | M.D. Anderson Cancer Center | 20 | 2024-09-11 | 2026-10-06 | |
| Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica Inflammatory Rheumatism, 18-FDG | Unknown | University Hospital, Brest | 210 | 2024-09-01 | 2024-08-20 | |
| Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) Secukinumab - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 162 | 2024-06-28 | 2026-10-14 |
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR Secukinumab - Giant Cell Arteritis, Polymyalgia Rheumatica | Phase 1 | Completed | Novartis Pharmaceuticals | 65 | 2024-03-27 | 2026-04-01 |
| Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica Prednisone+Tofacitinib, Prednisone - Polymyalgia Rheumatica | Phase 3 | Completed | Zhejiang University | 104 | 2024-01-20 | 2026-09-08 |
| DANIsh VASculitis Database (DANIVAS) Giant Cell Arteritis, Polymyalgia Rheumatica | Recruiting | Aarhus University Hospital | 3000 | 2023-11-10 | 2024-01-24 |
Showing 20 of 68. Sign in to see all of them.
Giant Cell Arteritis (24) · Arthritis, Rheumatoid (10) · Arthritis, Psoriatic (8) · Rheumatic Diseases (7) · Spondylitis, Ankylosing (6) · Vasculitis (6) · Lupus Erythematosus, Systemic (5) · Polymyositis (5) · Arthritis, Juvenile (4) · Autoimmune Diseases (4) · Crohn Disease (4) · Dermatomyositis (4) · Multiple Sclerosis (4) · Myositis (4)
Muscular Diseases (68) · Skin and Connective Tissue Diseases (68) · Musculoskeletal Diseases (67) · Connective Tissue Diseases (65) · Rheumatic Diseases (61) · Immune System Diseases (27) · Autoimmune Diseases of the Nervous System (26) · Nervous System Diseases (26) · Skin Diseases (26) · Cardiovascular Diseases (25) · Skin Diseases, Vascular (25) · Arteritis (24) · Autoimmune Diseases (24) · Brain Diseases (24) · Central Nervous System Diseases (24)
Prednisone (7) · secukinumab (6) · tocilizumab (5) · Prednisolone (4) · Rituximab (3) · Abatacept (2) · Etanercept (2) · Flow Cytometry (2) · Glucocorticoids (2) · Hydrocortisone (2) · Infliximab (2) · Leflunomide (2) · Positron Emission Tomography Computed Tomography (2) · Sodium Chloride (2) · canakinumab (2)
University Hospital, Brest (10) · Novartis Pharmaceuticals (5) · University of Bonn (3) · Aarhus University Hospital (2) · Kresten Krarup Keller (2) · Sanofi (2) · Sint Maartenskliniek (2) · Sparrow Pharmaceuticals (2) · Aalborg University (1) · AbbVie (1) · Alliance Foundation Trials, LLC. (1) · Bispebjerg Hospital (1) · Bnai Zion Medical Center (1) · Centre Hospitalier Universitaire Dijon (1) · Dartmouth-Hitchcock Medical Center (1)
France (17) · United States (17) · Germany (12) · Denmark (11) · Netherlands (9) · United Kingdom (9) · Italy (7) · Spain (7) · Belgium (5) · Canada (5) · Switzerland (5) · Australia (4) · Czechia (4) · Hungary (4) · Japan (4)
David Katz (2) · Aatke van der Maas (1) · Aatke van der Maas, MD PhD (1) · Andrew McGovern, MD (1) · Ann Morgan (1) · Berit Dalsgaard Nielsen, Ass prof (1) · Divi Cornec (1) · E.M. Colin (1) · Elisabeth Brouwer (1) · Gerald S. Harris, M.D. (1)
PMID 39400109, PMID 16914703, PMID 17407214, PMID 17557758, PMID 19955046, PMID 20854662, PMID 21569559, PMID 22894827, PMID 24189842, PMID 24489611, PMID 25396066, PMID 25592534, PMID 25902790, PMID 26929219, PMID 30877202, PMID 33301930, PMID 34785540, PMID 34909566, PMID 35157313, PMID 35210264, PMID 36125471, PMID 36604153, PMID 37792612, PMID 38095675, PMID 38251563, PMID 38563881, PMID 39026552, PMID 39180419, PMID 40131424, PMID 40307615, PMID 40544861, PMID 41264768, PMID 41638742, PMID 42234540, PMID 42276802, PMID 42767765, PMID 518143, PMID 9009973
2023 (3), 2016 (1), 2017 (1)